Evidence-to-impact map
Advancements, growth, technology and impact
Portfolio overview
Executive signal
Cancer care is advancing through better selection, selective intensification and lower treatment burden.
Phase III efficacy signals are emerging alongside de-escalation, personalized manufacturing and AI-enabled care delivery. The adoption test remains benefit versus toxicity, cost, complexity and unequal access.
Decision lens
What changes first?
Cross-portfolio comparison
Measured value and constraints
0 advances shown Select up to three for direct comparison.
Commercialization lens
India availability is indication-specific.
A product may be marketed in India while the ASCO study regimen remains off-label or investigational. Converted US prices are shown only as context and are not Indian market prices.
Illustrative conversion used
₹95.4 / US$
June 2026 reference
Access, price and launch
India commercialization tracker
Implementation gap
Operational performance vs clinical proof
Global oncology
Equity and system capacity
Brazil · prostate cancer
670,205
men treated in the public system; racial differences persisted in stage, local treatment and recorded expenditure.
Kyrgyzstan · cancer burden
+21.6%
increase in reported new cases from 2020 to 2024, increasing pressure on diagnostics and treatment capacity.
One year later · status at 9 June 2026
Which ASCO 2025 signals actually moved forward?
This selected tracker follows major practice-shaping molecules and regimens from ASCO 2025 through publication, guidelines, regulatory review and approval. A positive conference result is not counted as adoption until a later milestone is verified.
0programs tracked
Selected, not exhaustive
Program register
Evidence, regulation and next catalyst
Conference-to-care narratives
What happened after the presentation?
What the year changed
Follow-through assessment
Method
How status was assigned
Approved means a regulator has authorized the ASCO regimen and population.
Under review means a formal application or positive committee opinion is verified, but final authorization may still be pending.
Guideline signal means clinical use may advance before a new label, but regulatory and reimbursement status can differ.
Ongoing development includes publication, follow-up or further trials without verified approval for the studied use.